CLINICAL AND THERAPEUTIC STUDIES OF THE RHEUMATIC DISEASES

我们正在进行一系列的临床研究，患者患有 系统性红斑狼疮解决与疾病相关的问题 发病机制、流行病学、治疗和共病。一大群人 狼疮性肾炎的患者在过去的几年里聚集在一起 几十年来参与了长期的随机试验 皮质类固醇和免疫抑制药。这些研究已经 记录了静脉注射环磷酰胺的重要作用 重症增生性肾炎患者肾功能的保护 狼疮性肾炎。对这些患者的延长随访是 正在确定肾炎和晚期肾炎的复发率 免疫抑制的并发症。我们还感兴趣的还有 在患者身上进行有前景的治疗方法的I/II期临床试验 患有狼疮性肾炎。在过去的一年里，我们完成了关于 核苷类似物2-氯-2‘-脱氧腺苷与重组人 DNA酶。目前正在进行研究，以评估与 骨质疏松症和血管血栓事件的发展。

We are conducting a series of clinical investigations in patients with systemic lupus erythematosus to address questions related to disease pathogenesis, epidemiology, therapy and co-morbidities. A large cohort of patients with lupus nephritis has been assembled over the past several decades who have participated in long-term, randomized trials of corticosteroids and immunosuppressive drugs. These studies have documented the important role of intravenous cyclophosphamide in the preservation of renal function in patients with severe, proliferative lupus glomerulonephritis . Extended follow-up of these patients is ongoing to ascertain rates of relapse of the nephritis and late complications of immune suppression. We are also interested in conducting phase I/II clinical trials of promising therapies in patients with lupus nephritis. During the past year we have completed studies of the nucleoside analog 2-chloro-2'deoxyadenosine and recombinant human DNase. Studies are underway to assess risk factors associated with the development of osteoporosis and vascular thrombotic events.